echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The market scale is more than 50 billion, and the market of diabetes drugs in China will be improved day by day

    The market scale is more than 50 billion, and the market of diabetes drugs in China will be improved day by day

    • Last Update: 2018-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of chinapharma.com] according to the domestic public data, the sales terminal market of domestic antidiabetic drugs increased by 6.95% year on year in 2017, which has exceeded RMB 50 billion According to other statistics, in 2017, the number of diabetes drug terminals in public hospitals in key cities in China reached nearly 4 billion There will be a broad market space for diabetic drugs in China Diabetes is a chronic disease, the pathogenesis is that the pancreas can not produce enough insulin or the pancreas can not use its insulin correctly Diabetic complications can lead to serious consequences such as myocardial infarction, cerebral hemorrhage, blindness, renal failure and lower limb amputation, which is one of the main risk factors affecting human life According to the eighth edition of the global diabetes map released by the International Diabetes League, the number of diabetic patients in the world aged 20-79 years has reached 425 million in 2017 It is estimated that by 2045, the number of diabetic patients will reach 629 million With the aging of population and the change of life style, diabetes has become an epidemic disease from rare disease The prevalence of diabetes soared from 0.67% in 1980 to 10.4% in 2013 In the past 10 years, the incidence rate of diabetes has increased rapidly, and the market for diabetes treatment has been expanding It is reported that under the framework of China's medical security system, the national public medical institutions are the main market for diabetes drugs, accounting for 62% of the total market share, 24% of the retail terminal market share, and 14% of the other consumer terminals share In recent years, China's diabetes has shown a rapid growth trend, from 0.6% in 1980 to 11.6% of the current diabetes incidence rate However, the industry has said that although China's diabetes management is severe, anti diabetes drugs are becoming more and more perfect It is reported that 33 diabetes drugs are included in the new version of the national health insurance catalogue, including 12 insulin drugs and 21 type 2 diabetes hypoglycemic drugs Among them, 8 new hypoglycemic drugs for type 2 diabetes mellitus increased, with a growth rate of 61.54% from quantitative analysis They are composed of biguanides, sulfonylurea derivatives, α - glucosidase inhibitors, thiazolidinediones (TZD, glitazone), dipeptidyl peptidase-4 (DPP-4) inhibitors, human glucagon like peptide-1 (GLP-1) receptor agonists, aldose reductase inhibitors and non sulfonylurea insulin secretagogues And so on In addition, the drugs for painful diabetic peripheral neuropathy were also included The author also learned that the market of oral hypoglycemic drugs in China continued to grow steadily In 2017, the market scale of oral hypoglycemic drugs in sample hospitals reached 2.944 billion yuan Acarbose, dimethylbis arc, glimepiride, repaglinide and gliclazide ranked the top five, with a market share of more than 80% Among them, acarbose ranked lower than oral hypoglycemic drugs, with a market share of 37% in 2017 With the increasing attention to diabetic patients in China, the market of diabetic drugs will be more and more perfect It is reported that recently, a pharmaceutical company announced that its diabetes drug metformin hydrochloride tablet was approved by the State Drug Administration to pass the quality and efficacy consistency evaluation of generic drugs, becoming the first enterprise in the mainland to apply for and pass the supplementary application according to the consistency evaluation According to the company, the product is the basic drug for the treatment of diabetes According to the research results in recent years, in addition to the hypoglycemic effect, it also has the effects of cardiovascular protection and improvement of non-alcoholic fatty liver disease Because of its advantages in efficacy and accessibility, the drug has been listed as the first-line medication in the prevention and treatment guidelines for type 2 diabetes formulated by Chinese and foreign professional academic organizations In addition, a pharmaceutical company said that the company focuses on the oral hypoglycemic drug market, creates a strong domestic diabetes pipeline to drive the upgrading of diabetes drugs, and is expected to drive the market expansion to replace imports With the improvement of diabetes drug market and the approval of new products, the future diabetes drug market is expected to achieve rapid growth.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.